RNA-binding protein PSF functions as an epigenetic modifier by interacting with long noncoding RNAs and the
corepressor complex. PSF also promotes RNA splicing events to enhance oncogenic signals. In this study, we conducted an in vitro chemical array screen and identified multiple small molecules that interact with PSF. Several molecules inhibited
RNA binding by PSF and decreased
prostate cancer cell viability. Among these molecules and its derivatives was a promising molecule, No. 10-3 [7,8-dihydroxy-4-(4-methoxyphenyl)chromen-2-one], that was the most effective at blocking PSF
RNA-binding ability and suppressing treatment-resistant prostate and
breast cancer cell proliferation. Exposure to No. 10-3 inhibited PSF target gene expression at the
mRNA level. Treatment with No. 10-3 reversed epigenetically repressed PSF downstream targets, such as cell-cycle inhibitors, at the transcriptional level.
Chromatin immunoprecipitation sequencing in
prostate cancer cells revealed that No. 10-3 enhances
histone acetylation to induce expression of apoptosis as well as cell-cycle inhibitors. Furthermore, No. 10-3 exhibited antitumor efficacy in a
hormone therapy-resistant
prostate cancer xenograft mouse model, suppressing treatment-resistant
tumor growth. Taken together, this study highlights the feasibility of targeting PSF-mediated epigenetic and RNA-splicing activities for the treatment of aggressive
cancers. SIGNIFICANCE: This study identifies small molecules that target PSF-
RNA interactions and suppress
hormone therapy-refractory
cancer growth, suggesting the potential of targeting PSF-mediated gene regulation for
cancer treatment.